Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Dec;8(23):1613.
doi: 10.21037/atm-20-3982.

Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer

Annemarie F Shepherd  1   2 , Isabel R Preeshagul  3 , Narek Shaverdian  1 , Abraham J Wu  1 , Daphna Y Gelblum  1 , Daniel R Gomez  1 , Andreas Rimner  1 , Charles B Simone 2nd  1   2
Affiliations
Editorial

Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer

Annemarie F Shepherd et al. Ann Transl Med. 2020 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-3982). AFS reports personal fees from ASCO, from null, outside the submitted work. IRP reports other from AstraZeneca, from null, outside the submitted work. Dr. Shaverdian reports grants from Novartis, from null, outside the submitted work. AJW reports grants from CivaTech Oncology, Inc., personal fees from AstraZeneca, personal fees from AlphaTau Medical, outside the submitted work. Dr. Gomez reports grants from Boehringer-Ingelheim, grants from Varian Medical Systems, grants from AstraZeneca, grants from Merck, grants from Bristol Myers Squibb, outside the submitted work. AR reports grants and personal fees from Varian Medical Systems, grants from Boehringer Ingelheim, grants from Pfizer, grants and personal fees from AstraZeneca, grants and personal fees from Merck, personal fees from Research to Practice, personal fees from Cybrexa, personal fees from MoreHealth, non-financial support from Phillips/Elekta, from null, outside the submitted work. Dr. Simone serves as an unpaid editorial board member of Annals of Translational Medicine from Dec 2018 to Nov 2020, and he reports personal fees from Varian Medical Systems, outside the submitted work. The other author has no conflicts of interest to declare.

Comment on

  • Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).
    Liang W, Cai K, Chen C, Chen H, Fang W, Fu J, Fu X, Gao S, Hu J, Huang Y, Jiang G, Jiao W, Li S, Li G, Li H, Li H, Li X, Liang N, Liu D, Liu H, Liu J, Liu L, Liu Y, Luo Q, Ma H, Mao W, Peng Z, Qiao G, Shao G, Tan L, Tan Q, Wang Q, Wang C, Wu Q, Xu S, Xu S, Xu L, Yang Y, Yu F, Zhang B, Zhang L, Zhao B, Zhi X, Brunelli A, Petersen RH, Liu CC, Ricciuti B, Metro G, Tuzi A, Suter MB, Evison M, Seki N, Sasada S, Izumo T, Cho WC, He J; written on behalf of National Clinical Research Center for Respiratory Disease; Thoracic Surgery Branch of China International Exchange and Promotion Association for Medical and Healthcare; Chinese Alliance Against Lung Cancer; AME Thoracic Surgery Collaborative Group. Liang W, et al. Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14. Transl Lung Cancer Res. 2019. PMID: 32010594 Free PMC article. Review. No abstract available.

References

    1. American Cancer Society. Facts and Figures 2020. Available online: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts...
    1. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14. 10.1097/JTO.0b013e31812f3c1a - DOI - PubMed
    1. Kris MG, Gaspar LE, Chaft JE, et al. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol. 2017;35:2960-74. 10.1200/JCO.2017.72.4401 - DOI - PubMed
    1. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv1-21. 10.1093/annonc/mdx222 - DOI - PubMed
    1. Tan DS, Yom SS, Tsao MS, et al. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol 2016;11:946-63. 10.1016/j.jtho.2016.05.008 - DOI - PubMed